JP2008516974A5 - - Google Patents

Download PDF

Info

Publication number
JP2008516974A5
JP2008516974A5 JP2007536972A JP2007536972A JP2008516974A5 JP 2008516974 A5 JP2008516974 A5 JP 2008516974A5 JP 2007536972 A JP2007536972 A JP 2007536972A JP 2007536972 A JP2007536972 A JP 2007536972A JP 2008516974 A5 JP2008516974 A5 JP 2008516974A5
Authority
JP
Japan
Prior art keywords
methoxy
phenyl
pyrimidin
ethylamino
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007536972A
Other languages
English (en)
Japanese (ja)
Other versions
JP4970274B2 (ja
JP2008516974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/037148 external-priority patent/WO2006044732A2/en
Publication of JP2008516974A publication Critical patent/JP2008516974A/ja
Publication of JP2008516974A5 publication Critical patent/JP2008516974A5/ja
Application granted granted Critical
Publication of JP4970274B2 publication Critical patent/JP4970274B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007536972A 2004-10-15 2005-10-14 プロスタグランジンd2受容体アンタゴニストとしての2,6−置換−4−一置換アミノ−ピリミジン Expired - Fee Related JP4970274B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61927204P 2004-10-15 2004-10-15
US60/619,272 2004-10-15
PCT/US2005/037148 WO2006044732A2 (en) 2004-10-15 2005-10-14 2, 6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2008516974A JP2008516974A (ja) 2008-05-22
JP2008516974A5 true JP2008516974A5 (enExample) 2008-07-31
JP4970274B2 JP4970274B2 (ja) 2012-07-04

Family

ID=36072155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007536972A Expired - Fee Related JP4970274B2 (ja) 2004-10-15 2005-10-14 プロスタグランジンd2受容体アンタゴニストとしての2,6−置換−4−一置換アミノ−ピリミジン

Country Status (35)

Country Link
US (2) US7517889B2 (enExample)
EP (1) EP1891019B1 (enExample)
JP (1) JP4970274B2 (enExample)
KR (1) KR101280268B1 (enExample)
CN (1) CN101039920B (enExample)
AR (1) AR053770A1 (enExample)
AU (1) AU2005295502B2 (enExample)
BR (1) BRPI0516482A (enExample)
CA (1) CA2583742C (enExample)
CR (1) CR9003A (enExample)
DK (1) DK1891019T3 (enExample)
EC (1) ECSP077398A (enExample)
ES (1) ES2392091T3 (enExample)
GT (1) GT200500284A (enExample)
HN (1) HN2005000795A (enExample)
IL (1) IL182090A (enExample)
MA (1) MA29071B1 (enExample)
MX (1) MX2007003155A (enExample)
MY (2) MY157036A (enExample)
NO (1) NO339772B1 (enExample)
NZ (1) NZ553919A (enExample)
PA (1) PA8649801A1 (enExample)
PE (1) PE20060936A1 (enExample)
PL (1) PL1891019T3 (enExample)
PT (1) PT1891019E (enExample)
RU (1) RU2417990C2 (enExample)
SG (1) SG156653A1 (enExample)
SI (1) SI1891019T1 (enExample)
SV (1) SV2006002272A (enExample)
TN (1) TNSN07098A1 (enExample)
TW (1) TWI372751B (enExample)
UA (1) UA88485C2 (enExample)
UY (1) UY29167A1 (enExample)
WO (1) WO2006044732A2 (enExample)
ZA (1) ZA200702209B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600457A (es) * 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2
DOP2007000068A (es) * 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
NZ579892A (en) * 2007-03-30 2012-03-30 Sanofi Aventis Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors
BRPI0810719A8 (pt) * 2007-04-30 2016-03-08 Abbott Lab Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1
EP2014657A1 (de) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
ATE531699T1 (de) 2007-06-29 2011-11-15 Sanofi Sa Verfahren zur herstellung von 2-(3-ä6-ä2-(2,4-
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
WO2009055730A1 (en) * 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
MX2010005033A (es) * 2007-11-06 2010-05-27 Du Pont Aminas heterociclicas fungicidas.
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
WO2009086277A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
EP2254415B1 (en) 2008-02-19 2013-01-23 Janssen Pharmaceutica, N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
US20110053949A1 (en) * 2008-04-17 2011-03-03 Pfizer Inc. 4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
MX2012010038A (es) 2010-03-16 2012-10-01 Aventis Pharma Inc Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2.
CA2793223A1 (en) * 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. Substituted pyrimidines as prostaglandin d2 receptor antagonists
UY33304A (es) * 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ, インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
CA2805452C (en) 2010-07-05 2018-07-31 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2621276B1 (en) * 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
PH12013502516A1 (en) * 2011-06-06 2017-08-23 Chiesi Farm Spa Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
FR2983859B1 (fr) 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
TW201331179A (zh) 2011-12-21 2013-08-01 Actelion Pharmaceuticals Ltd 雜環衍生物及其作為前列腺素d2受體調節劑之用途
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
EP2885307A1 (en) 2012-07-05 2015-06-24 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
MX376108B (es) 2012-12-20 2025-03-07 Tempest Therapeutics Inc Compuestos de triazolona y usos de los mismos.
RS62649B1 (sr) 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
AU2014315151A1 (en) 2013-09-06 2016-03-03 Inception 2, Inc. Triazolone compounds and uses thereof
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
JP2018123058A (ja) * 2015-06-08 2018-08-09 石原産業株式会社 ジフルオロメチレン化合物
CN109734651A (zh) * 2015-07-06 2019-05-10 江苏恩华药业股份有限公司 阿芬太尼、舒芬太尼的制备方法及用于制备阿芬太尼、舒芬太尼的化合物
US10329277B2 (en) * 2015-07-16 2019-06-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
WO2018107158A1 (en) * 2016-12-09 2018-06-14 Celtaxsys, Inc. Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
GB201807898D0 (en) * 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
CA3124353A1 (en) * 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN110642880B (zh) * 2019-10-11 2021-12-31 长沙麓兴生物科技有限公司 一种氮未取代吡唑和吲唑类硼酸的制备方法
WO2021113710A1 (en) 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
JP2023539113A (ja) * 2020-08-18 2023-09-13 サイビン アイアールエル リミテッド フェネチルアミン誘導体、組成物およびその使用方法
CN116507611A (zh) * 2020-11-06 2023-07-28 佩勒梅德有限公司 新型衣壳组装抑制剂
CN117599052B (zh) * 2023-07-25 2026-07-24 温州医科大学附属眼视光医院 Ptgds的抑制剂在制备治疗白内障药物上的应用
US12220411B1 (en) 2023-07-25 2025-02-11 The Eye Hospital Of Wenzhou Medical University Application of PTGDS inhibitor in preparation of drug for treating cataracts
TW202604507A (zh) 2024-05-02 2026-02-01 瑞士商愛杜西亞製藥有限公司 經n-取代之吲哚衍生物的結晶形式

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH499528A (de) * 1965-10-22 1970-11-30 Ciba Geigy Ag Verfahren zur Herstellung neuer Pyrimidine
GB1143167A (en) * 1967-01-25 1969-02-19 Ucb Sa Derivatives of pyrimidine
DE4031798A1 (de) * 1990-10-08 1992-04-09 Hoechst Ag Pyridylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
DE4031792A1 (de) * 1990-10-08 1991-04-25 Franz Reiner Dipl Phy Thedieck Indikator-element aus festen bestandteilen
FR2753378B1 (fr) * 1996-09-17 1998-11-20 Oreal Utilisation dans une composition en tant que stimulateur de tyrosinase d'au moins un derive de pyrimidine 3-oxyde, substitue en 6
US6169086B1 (en) * 1997-01-27 2001-01-02 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
ATE250053T1 (de) * 1999-07-15 2003-10-15 Pharmacopeia Inc Bradikinin b1 rezeptor antagonisten
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
WO2002092090A1 (en) * 2001-05-14 2002-11-21 Bristol-Myers Squibb Pharma Company Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
US20030208067A1 (en) * 2001-05-30 2003-11-06 Cao Sheldon Xiaodong Inhibitors of protein kinase for the treatment of disease
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
WO2004017920A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Novel biphenyl and biphenyl-like cannabinoids
AU2003265663A1 (en) 2002-08-23 2004-03-11 University Of Connecticut Keto cannabinoids with therapeutic indications
US20070155701A1 (en) * 2002-08-23 2007-07-05 Alexandros Makriyannis Keto cannabinoids with therapeutic indications
CA2505361A1 (en) * 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
KR20060052806A (ko) * 2003-07-25 2006-05-19 시바 스폐셜티 케미칼스 홀딩 인코포레이티드 항균제로서 치환된 2,4-비스(알킬아미노)피리미딘 또는-퀴나졸린의 용도
AU2005225471B2 (en) * 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
ES2364340T3 (es) * 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
EP1805142A4 (en) * 2004-09-23 2009-06-10 Reddy Us Therapeutics Inc PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
AU2005309566A1 (en) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or Rho kinase
JP2008534472A (ja) * 2005-03-22 2008-08-28 ノイロサーチ アクティーゼルスカブ カリウムチャンネル調節剤としてのピラゾリル−ピリミジン及びその医学的使用
GT200600457A (es) * 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2

Similar Documents

Publication Publication Date Title
CA2583742A1 (en) 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists
CN101492416B (zh) 影响葡糖激酶的化合物
JP2020516671A5 (enExample)
US7211594B2 (en) Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
RU2019132212A (ru) Селективные ингибиторы hdac6
RU2012116207A (ru) Производные индола в качестве модуляторов crac
US9580438B2 (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders
AU2004266719A1 (en) Methods of treating COPD and pulmonary hypertension
JP2016522246A5 (enExample)
JP2005536458A5 (enExample)
JP2004531473A5 (enExample)
RU2003118448A (ru) Производные замещенного триазолдиамина и их применение в качестве ингибиторов киназы
JP2007530690A5 (enExample)
JP2017537948A5 (enExample)
JP2010504280A5 (enExample)
JP2008500336A5 (enExample)
KR20090087916A (ko) 4-페닐-6-(2,2,2-트리플루오로-1-페닐에톡시)피리미딘계 화합물 및 그의 사용 방법
JP2016523976A5 (enExample)
JP2020520354A5 (enExample)
JP2014523400A5 (enExample)
AU2011238616A1 (en) Multisubstituted aromatic compounds as inhibitors of thrombin
JP2022553351A5 (enExample)
JP2009541268A5 (enExample)
US20170107206A1 (en) Modulators of atp-binding cassette transporters
US20070185163A1 (en) Imidazol derivatives of piperidine as histamine antagonists